SoFi stock falls after announcing $1.5B public offering of common stock
NATICK, Mass. - A new peer-reviewed study published in Obesity Surgery shows that patients using the Allurion Smart Capsule combined with lifestyle intervention achieved significantly greater weight loss compared to lifestyle intervention alone.
The case-controlled study involving 1,143 patients with a body mass index of 30 kg/m² or higher found that those treated with the Allurion Smart Capsule reached an average weight reduction of 20% at 36 weeks, comparable to results seen with bariatric surgery and high-dose GLP-1 therapy.
Researchers also reported improved body composition metrics, with patients experiencing greater fat mass loss and visceral fat reduction without adverse effects on muscle mass.
"This study underscores the synergistic effects of the Allurion Smart Capsule with an individualized lifestyle intervention," said Dr. Yannis Raftopoulos, Director of the Weight Management Program at Holyoke Medical Center and Principal Investigator of the study.
The Allurion Smart Capsule is designed to be swallowed during an outpatient visit, filled once in the stomach, and pass naturally after four months. When used with Allurion's Virtual Care Suite, patients receive digital support and remote monitoring.
According to the company, the device demonstrated a safety profile better than bariatric surgery and GLP-1 therapy at a substantially lower cost.
The Allurion Smart Capsule remains an investigational device in the United States, according to information provided in the company's press release statement. Despite maintaining impressive gross profit margins of approximately 61%, InvestingPro data shows Allurion is quickly burning through cash with a significant debt burden of $83.29 million.
Allurion Technologies, Inc. trades on the New York Stock Exchange under the ticker NYSE:ALUR. The stock, currently trading at $1.39, has fallen nearly 88% over the past year, though InvestingPro analysis suggests it may be undervalued based on Fair Value estimates. Investors can access comprehensive analysis and 17 additional ProTips in the Pro Research Report, which transforms complex financial data into actionable intelligence for smarter investment decisions.
In other recent news, Allurion Technologies Inc. reported a significant decline in its Q3 2025 revenue, which fell to $2.7 million from $5.4 million during the same period last year. Despite this revenue drop, the company successfully reduced its operating loss by 22%, bringing it down to $9.6 million. This development comes amid ongoing market challenges that have impacted the company's financial performance. Additionally, Allurion Technologies announced a strategic distribution partnership with ProSurg Medical to expand its weight loss program in Brazil. This partnership aims to leverage ProSurg Medical's extensive experience and network in the Brazilian market, which includes over 300 hospitals. The collaboration is expected to enhance Allurion's presence and reach within the region. These recent developments highlight both the financial hurdles and strategic initiatives that Allurion Technologies is currently navigating.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.